Red Flag Alert – The 'Pricing' of Success for LeMaitre
Valued as a growing, durable medtech compounder, but has its model met its match?
Note: There will be no Wrap this week. And barring anything that absolutely, positively can’t wait, or my own urge to purge, I will be taking the next week off.
When I mentioned a few weeks ago that I was working on LeMaitre Vascular LMAT 0.00%↑, a medtech roll-up, my tease was that it’s an open-surgery approach to peripheral arterial disease amid growing endovascular competition.
As it turns out, that’s the least of its worries. And it’s anything BUT the story…
LeMaitre, in its own words, is “a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease.”
The company was founded in 1984 by the late George D. LeMaitre, whose invention of the vascular valvulotome was a game-changer in its day in the surgical treatment of peripheral arterial disease, or PAD… and was the launchpad for what the company has become.
The bullish narrative is that as the No. 1 or No. 2 player in most of its niches, LeMaitre is a durable, high-margin, organically growing, cash‑generating medtech compounder, with genuine operating leverage, sustainable pricing power, a runway for gross margin expansion and a strong enough balance sheet to fund continued M&A.
Or as the longer-form AI-generated summary of the bull case via my pals at Tenzing MEMO puts it…
LeMaitre Vascular, Inc. offers a compelling investment case based on its durable competitive position in niche vascular device markets, consistent double-digit revenue growth, and robust profitability. The company holds #1 or #2 share in 9 of 12 targeted markets, generating 85% of sales from these segments, and benefits from strong pricing power—recently achieving annual price increases well above inflation. Its direct sales model, now covering 95% of revenue, fosters close customer relationships and supports margin expansion, with gross margins reaching 72% and operating margins approaching 30%.
Management stability is notable, with the top executive team averaging over 20 years’ tenure and significant insider ownership, aligning interests with shareholders. The company has a proven track record of successful acquisitions and disciplined capital allocation, including regular dividend increases and a share repurchase program.
Growth prospects are underpinned by international expansion, new product launches, and further penetration of biologic implants. LeMaitre’s focused strategy, operational discipline, and strong balance sheet position it well for continued outperformance.
Sounds good on paper, but beyond just “good on paper,” the durability of its model is supported by the 10-year performance of its stock…
Ditto the headline numbers…
Dig a bit deeper, however, and you find a maturing roll-up built on 25 acquisitions over 28 years, with enough red flags to suggest that LeMaitre’s overall strategy and model appear to be increasingly stretched.
And that’s at a company that trades at roughly 35x last year’s earnings and 9x sales as if it’s somewhat business as usual.
Hint: it certainly doesn’t appear to be.
Let’s go through a few reasons why, keeping in mind the frustrating part about researching LeMaitre: This is a lotsa-technical-and-regulatory-nooks-and-crannies-and-moving-parts story, with the potential to do deep dives down one too many product-specific rabbit holes than I want to dive down… and likely more than you likely care about. So I’m just hitting on what, after taking a peek at most, I view as Red Flag highlights…